KRBPQ — Kiromic BioPharma, Inc.
$0.00
+$0.00 (+0.00%)
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer.
Market Cap
$265.00
Forward P/E
N/A
52-Week Range
N/A
KRBPQ Price History
Revenue vs. Net Income
$0
Revenue · FY2021
Annual. Net margin is shown under each year.
Free Cash Flow
-$22.2M
FCF · FY2021
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-93.6%
ROCE · FY2021
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
9.0x
Assets ÷ liabilities · FY2021
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
380.6K
Diluted shares · FY2021
Only one year of share data is available, so no change can be shown yet.
